faculty_name,faculty_email,publication_type,title,journal,year,doi,url,file_created
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,The Aldosterone Blockade for Health Improvement Evaluation in End-Stage Renal Disease (ACHIEVE) Trial: Rationale and Clinical Research Protocol.,Canadian Journal of Kidney Health and Disease,2025,10.1177/20543581251348187,https://experts.mcmaster.ca/display/publication3592889,2025-07-27T15:12:35.717771
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Effect of spirulina on risk of hospitalization among patients with COVID-19: the TOGETHER randomized trial.,American Journal of Clinical Nutrition,2024,10.1016/j.ajcnut.2024.06.016,https://experts.mcmaster.ca/display/publication3466456,2025-07-27T15:12:35.717773
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.,European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy,2024,10.1093/ehjcvp/pvae025,https://experts.mcmaster.ca/display/publication3478213,2025-07-27T15:12:35.717774
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Mortality and Morbidity in Adults With Rheumatic Heart Disease,Journal of the American Medical Association (JAMA),2024,10.1001/jama.2024.8258,https://experts.mcmaster.ca/display/publication3438809,2025-07-27T15:12:35.717775
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Stress Ulcer Prophylaxis during Invasive Mechanical Ventilation,New England Journal of Medicine,2024,10.1056/nejmoa2404245,https://experts.mcmaster.ca/display/publication3441537,2025-07-27T15:12:35.717776
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Matched vs Nonmatched Placebos in a Randomized Trial of COVID-19 Treatments,JAMA network open,2024,10.1001/jamanetworkopen.2024.10335,https://experts.mcmaster.ca/display/publication3433094,2025-07-27T15:12:35.717777
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,REVISE:Re-Evaluating theInhibition ofStressErosions in the ICU: a randomised trial protocol,BMJ Open,2023,10.1136/bmjopen-2023-075588,https://experts.mcmaster.ca/display/publication3309193,2025-07-27T15:12:35.717778
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Pegylated Interferon Lambda for Covid-19,New England Journal of Medicine,2023,10.1056/nejmc2303519,https://experts.mcmaster.ca/display/publication3243902,2025-07-27T15:12:35.717779
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,"Global Variations in Heart Failure Etiology, Management, and Outcomes",Journal of the American Medical Association (JAMA),2023,10.1001/jama.2023.5942,https://experts.mcmaster.ca/display/publication3238157,2025-07-27T15:12:35.717780
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19,ACP journal club,2023,10.7326/m22-3305,https://experts.mcmaster.ca/display/publication3067607,2025-07-27T15:12:35.717781
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Hydroxychloroquine for treatment of non‐hospitalized adults withCOVID‐19: A meta‐analysis of individual participant data of randomized trials,Clinical and Translational Science,2023,10.1111/cts.13468,https://experts.mcmaster.ca/display/publication2776412,2025-07-27T15:12:35.717782
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Early Treatment with Pegylated Interferon Lambda for Covid-19,New England Journal of Medicine,2023,10.1056/nejmoa2209760,https://experts.mcmaster.ca/display/publication2834957,2025-07-27T15:12:35.717783
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Early Treatment with Fluvoxamine among Patients with COVID-19: A Cost-Consequence Model,American Journal of Tropical Medicine and Hygiene,2023,10.4269/ajtmh.22-0106,https://experts.mcmaster.ca/display/publication2746340,2025-07-27T15:12:35.717784
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Ivermectin Treatment for Covid-19,New England Journal of Medicine,2022,10.1056/nejmc2207995,https://experts.mcmaster.ca/display/publication2776396,2025-07-27T15:12:35.717785
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Toward a New Paradigm of North–South and South–South Partnerships for Pandemic Preparedness: Lessons Learned from COVID-19 and Other Outbreaks,American Journal of Tropical Medicine and Hygiene,2022,10.4269/ajtmh.22-0466,https://experts.mcmaster.ca/display/publication2658539,2025-07-27T15:12:35.717786
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Correction to Lancet Glob Health 2021; 10: e42–51,The Lancet Global Health,2022,10.1016/s2214-109x(22)00336-9,https://experts.mcmaster.ca/display/publication3264929,2025-07-27T15:12:35.717787
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,"Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.",Circulation,2022,10.1161/CIRCULATIONAHA.121.057807,https://experts.mcmaster.ca/display/publication3478214,2025-07-27T15:12:35.717788
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Effect of Early Treatment with Ivermectin among Patients with Covid-19,New England Journal of Medicine,2022,10.1056/nejmoa2115869,https://experts.mcmaster.ca/display/publication2190573,2025-07-27T15:12:35.717789
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Evaluating COVID-19 vaccines in the real world,The Lancet,2022,10.1016/s0140-6736(22)00194-5,https://experts.mcmaster.ca/display/publication2185337,2025-07-27T15:12:35.717790
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Fluvoxamine for the treatment of COVID-19 – Author's reply,The Lancet Global Health,2022,10.1016/s2214-109x(21)00588-x,https://experts.mcmaster.ca/display/publication2443321,2025-07-27T15:12:35.717791
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Resilient Clinical Trial Infrastructure in Response to the COVID-19 Pandemic: Lessons Learned from the TOGETHER Randomized Platform Clinical Trial,American Journal of Tropical Medicine and Hygiene,2022,10.4269/ajtmh.21-1202,https://experts.mcmaster.ca/display/publication2168684,2025-07-27T15:12:35.717792
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial,The Lancet Regional Health - Americas,2022,10.1016/j.lana.2021.100142,https://experts.mcmaster.ca/display/publication2179626,2025-07-27T15:12:35.717793
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial",The Lancet Global Health,2022,10.1016/s2214-109x(21)00448-4,https://experts.mcmaster.ca/display/publication2153630,2025-07-27T15:12:35.717794
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,"Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial",The Lancet Diabetes and Endocrinology,2022,10.1016/s2213-8587(21)00292-8,https://experts.mcmaster.ca/display/publication2155578,2025-07-27T15:12:35.717795
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Error in Visual Abstract,JAMA network open,2021,10.1001/jamanetworkopen.2021.30442,https://experts.mcmaster.ca/display/publication2776406,2025-07-27T15:12:35.717796
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Effect of Early Treatment with Fluvoxamine on Risk of Emergency Care and Hospitalization Among Patients with COVID-19: The TOGETHER Randomized Platform Clinical Trial,,2021,10.1101/2021.08.19.21262323,https://experts.mcmaster.ca/display/publication2776411,2025-07-27T15:12:35.717797
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol,Journal of the American College of Cardiology,2021,10.1016/j.jacc.2021.04.102,https://experts.mcmaster.ca/display/publication2049477,2025-07-27T15:12:35.717798
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Three week compared to seven week run-in period length and the assessment of pre-randomization adherence: A study within a trial,Contemporary Clinical Trials,2021,10.1016/j.cct.2021.106466,https://experts.mcmaster.ca/display/publication1980491,2025-07-27T15:12:35.717799
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,How COVID-19 has fundamentally changed clinical research in global health,The Lancet Global Health,2021,10.1016/s2214-109x(20)30542-8,https://experts.mcmaster.ca/display/publication1966711,2025-07-27T15:12:35.717800
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19,JAMA network open,2021,10.1001/jamanetworkopen.2021.6468,https://experts.mcmaster.ca/display/publication1967683,2025-07-27T15:12:35.717801
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,A systematic review of the literature on the relationship between ACE2 and SARS-CoV infection in animal models,University of Toronto Medical Journal,2021,,https://experts.mcmaster.ca/display/publication1968110,2025-07-27T15:12:35.717802
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial",The Lancet,2020,10.1016/s0140-6736(20)32339-4,https://experts.mcmaster.ca/display/publication1940555,2025-07-27T15:12:35.717803
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19,American Journal of Tropical Medicine and Hygiene,2020,10.4269/ajtmh.20-0995,https://experts.mcmaster.ca/display/publication1924139,2025-07-27T15:12:35.717804
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF,American Journal of Medicine,2019,10.1016/j.amjmed.2019.06.008,https://experts.mcmaster.ca/display/publication1654157,2025-07-27T15:12:35.717805
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes,Circulation,2019,10.1161/circulationaha.119.042551,https://experts.mcmaster.ca/display/publication1684864,2025-07-27T15:12:35.717806
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial,Circulation. Cardiovascular Quality and Outcomes,2019,10.1161/circoutcomes.119.005858,https://experts.mcmaster.ca/display/publication1686862,2025-07-27T15:12:35.717807
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,P5522ST elevation myocardial infarction networks: relationship of hub-spoke distance with transfer time and clinical outcomes in rescue PCI,European Heart Journal,2019,10.1093/eurheartj/ehz746.0470,https://experts.mcmaster.ca/display/publication2776414,2025-07-27T15:12:35.717808
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial,European Heart Journal,2019,10.1093/eurheartj/ehz299,https://experts.mcmaster.ca/display/publication1676062,2025-07-27T15:12:35.717809
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,"Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial",The Lancet,2019,10.1016/s0140-6736(19)31887-2,https://experts.mcmaster.ca/display/publication1664173,2025-07-27T15:12:35.717810
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial,The Lancet Diabetes and Endocrinology,2019,10.1016/s2213-8587(19)30158-5,https://experts.mcmaster.ca/display/publication1668070,2025-07-27T15:12:35.717811
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Effect of Alirocumab on Mortality After Acute Coronary Syndromes,Circulation,2019,10.1161/circulationaha.118.038840,https://experts.mcmaster.ca/display/publication1671242,2025-07-27T15:12:35.717813
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial",The Lancet,2019,10.1016/s0140-6736(19)31149-3,https://experts.mcmaster.ca/display/publication1645036,2025-07-27T15:12:35.717814
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial",The Lancet,2019,10.1016/s0140-6736(19)31150-x,https://experts.mcmaster.ca/display/publication1645037,2025-07-27T15:12:35.717815
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF,American Heart Journal,2019,10.1016/j.ahj.2019.03.013,https://experts.mcmaster.ca/display/publication1642111,2025-07-27T15:12:35.717816
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry,Journal of the American Heart Association,2019,10.1161/jaha.118.010510,https://experts.mcmaster.ca/display/publication1624665,2025-07-27T15:12:35.717817
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,"Sharing best practices in applications of evidence-based medicine, problem-based learning and self-directed learning principles in medical training: A McMaster-Brazil collaboration workshop report",MedEdPublish,2019,10.15694/mep.2019.000067.1,https://experts.mcmaster.ca/display/publication2745895,2025-07-27T15:12:35.717818
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome,New England Journal of Medicine,2018,10.1056/nejmoa1801174,https://experts.mcmaster.ca/display/publication1676063,2025-07-27T15:12:35.717819
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry,Indian Heart Journal,2018,10.1016/j.ihj.2018.09.001,https://experts.mcmaster.ca/display/publication1639005,2025-07-27T15:12:35.717820
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness,New England Journal of Medicine,2018,10.1056/nejmoa1805090,https://experts.mcmaster.ca/display/publication1589921,2025-07-27T15:12:35.717821
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry,European Heart Journal,2018,10.1093/eurheartj/ehx730,https://experts.mcmaster.ca/display/publication1668531,2025-07-27T15:12:35.717822
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Incorporating evidence-based principles in medical training. Sharing experience with McMaster,MedEdPublish,2018,10.15694/mep.2018.0000269.1,https://experts.mcmaster.ca/display/publication2745897,2025-07-27T15:12:35.717823
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,"Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial",The Lancet,2018,10.1016/s0140-6736(17)32458-3,https://experts.mcmaster.ca/display/publication1476431,2025-07-27T15:12:35.717824
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial",The Lancet,2018,10.1016/s0140-6736(17)32409-1,https://experts.mcmaster.ca/display/publication1476430,2025-07-27T15:12:35.717825
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,"Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation",BMJ Open,2017,10.1136/bmjopen-2017-017157,https://experts.mcmaster.ca/display/publication1487549,2025-07-27T15:12:35.717826
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease,New England Journal of Medicine,2017,10.1056/nejmoa1709118,https://experts.mcmaster.ca/display/publication1446780,2025-07-27T15:12:35.717827
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF‐TIMI 48 Trial,Journal of the American Heart Association,2017,10.1161/jaha.117.006703,https://experts.mcmaster.ca/display/publication1672428,2025-07-27T15:12:35.717828
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients,New England Journal of Medicine,2017,10.1056/nejmoa1701488,https://experts.mcmaster.ca/display/publication1665557,2025-07-27T15:12:35.717829
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves,Circulation,2017,10.1161/circulationaha.116.026714,https://experts.mcmaster.ca/display/publication1687887,2025-07-27T15:12:35.717830
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry,BMJ Open,2017,10.1136/bmjopen-2016-014579,https://experts.mcmaster.ca/display/publication1669284,2025-07-27T15:12:35.717831
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation,Heart,2017,10.1136/heartjnl-2016-309832,https://experts.mcmaster.ca/display/publication840248,2025-07-27T15:12:35.717832
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention,Journal of the American College of Cardiology,2017,10.1016/j.jacc.2016.10.055,https://experts.mcmaster.ca/display/publication1749741,2025-07-27T15:12:35.717833
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation,Circulation: Arrhythmia and Electrophysiology,2017,10.1161/circep.116.004267,https://experts.mcmaster.ca/display/publication1687934,2025-07-27T15:12:35.717834
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin,Hypertension,2016,10.1161/hypertensionaha.116.07797,https://experts.mcmaster.ca/display/publication1694181,2025-07-27T15:12:35.717835
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD‐AF and treated with vitamin K antagonists,British Journal of Haematology,2016,10.1111/bjh.14084,https://experts.mcmaster.ca/display/publication840255,2025-07-27T15:12:35.717836
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events,Stroke,2016,10.1161/strokeaha.116.013540,https://experts.mcmaster.ca/display/publication1687888,2025-07-27T15:12:35.717837
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Cardioversion of Atrial Fibrillation inENGAGE AF‐TIMI48,Clinical Cardiology,2016,10.1002/clc.22537,https://experts.mcmaster.ca/display/publication1687889,2025-07-27T15:12:35.717838
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF,Journal of the American Heart Association,2016,10.1161/JAHA.115.002197,https://experts.mcmaster.ca/display/publication1639003,2025-07-27T15:12:35.717839
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry,PLoS ONE,2016,10.1371/journal.pone.0164076,https://experts.mcmaster.ca/display/publication840246,2025-07-27T15:12:35.717840
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,"Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial",The Lancet,2015,10.1016/s0140-6736(14)62225-x,https://experts.mcmaster.ca/display/publication1671819,2025-07-27T15:12:35.717841
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Does Sex Affect Anticoagulant Use for Stroke Prevention in Nonvalvular Atrial Fibrillation?,Circulation. Cardiovascular Quality and Outcomes,2015,10.1161/circoutcomes.114.001556,https://experts.mcmaster.ca/display/publication1639001,2025-07-27T15:12:35.717842
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Interaction Between Digoxin and Dronedarone in the PALLAS Trial,Circulation: Arrhythmia and Electrophysiology,2014,10.1161/circep.114.002046,https://experts.mcmaster.ca/display/publication871229,2025-07-27T15:12:35.717843
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Cardiac Structure and Function and Prognosis in Heart Failure With Preserved Ejection Fraction,Circulation. Heart Failure,2014,10.1161/circheartfailure.114.001583,https://experts.mcmaster.ca/display/publication2776397,2025-07-27T15:12:35.717844
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin,Stroke,2014,10.1161/strokeaha.114.006025,https://experts.mcmaster.ca/display/publication1687890,2025-07-27T15:12:35.717845
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,A Phase 3 Randomized Double-Blind Comparison of Ceftobiprole Medocaril Versus Ceftazidime Plus Linezolid for the Treatment of Hospital-Acquired Pneumonia,Clinical Infectious Diseases,2014,10.1093/cid/ciu219,https://experts.mcmaster.ca/display/publication2776398,2025-07-27T15:12:35.717846
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Edoxaban versus Warfarin in Patients with Atrial Fibrillation,New England Journal of Medicine,2013,10.1056/nejmoa1310907,https://experts.mcmaster.ca/display/publication150038,2025-07-27T15:12:35.717847
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes,New England Journal of Medicine,2013,10.1056/nejmoa1305889,https://experts.mcmaster.ca/display/publication1666235,2025-07-27T15:12:35.717848
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial,European Heart Journal,2013,10.1093/eurheartj/eht342,https://experts.mcmaster.ca/display/publication2776408,2025-07-27T15:12:35.717849
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Percutaneous revascularization and long term clinical outcomes of diabetic patients randomized in the Occluded Artery Trial (OAT),International Journal of Cardiology,2013,10.1016/j.ijcard.2013.02.004,https://experts.mcmaster.ca/display/publication2443322,2025-07-27T15:12:35.717850
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Management of acute coronary syndromes in developing countries: ACute Coronary Events—a multinational Survey of current management Strategies,American Heart Journal,2011,10.1016/j.ahj.2011.07.029,https://experts.mcmaster.ca/display/publication2776403,2025-07-27T15:12:35.717851
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Ecocardiograma sob estresse com dobutamina em pacientes assintomáticos com regurgitação aórtica,Arquivos Brasileiros de Cardiologia,2009,10.1590/s0066-782x2009000700010,https://experts.mcmaster.ca/display/publication2776404,2025-07-27T15:12:35.717852
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,III Diretriz sobre tratamento do infarto agudo do miocárdio,Arquivos Brasileiros de Cardiologia,2004,10.1590/s0066-782x2004002200001,https://experts.mcmaster.ca/display/publication2776405,2025-07-27T15:12:35.717853
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Dobutamine stress echocardiography for noninvasive assessment and risk stratification of patients with rheumatic mitral stenosis,Journal of the American College of Cardiology,2004,10.1016/j.jacc.2003.09.037,https://experts.mcmaster.ca/display/publication2776401,2025-07-27T15:12:35.717854
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Risk factors for myocardial infarction in Brazil,American Heart Journal,2003,10.1016/s0002-8703(03)00181-9,https://experts.mcmaster.ca/display/publication2776410,2025-07-27T15:12:35.717855
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,Usefulness of dobutamine stress echocardiography in detecting coronary artery disease in end-stage renal disease,American Journal of Cardiology,1995,10.1016/s0002-9149(99)80658-4,https://experts.mcmaster.ca/display/publication2776402,2025-07-27T15:12:35.717856
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,[Noninvasive evaluation of ischemia and viability after acute myocardial infarction].,Arquivos Brasileiros de Cardiologia,1995,,https://experts.mcmaster.ca/display/publication2776399,2025-07-27T15:12:35.717857
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,986-79 Identification of Coronary Artery Disease and Assessment of Prognosis in Patients with Chronic Renal Failure: Role of Dobutamine Stress Echocardiography,Journal of the American College of Cardiology,1995,10.1016/0735-1097(95)92730-s,https://experts.mcmaster.ca/display/publication2776415,2025-07-27T15:12:35.717858
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,[Echocardiographic diagnosis of hematoma compressing the right atrium in post-operative heart surgery].,Arquivos Brasileiros de Cardiologia,1993,,https://experts.mcmaster.ca/display/publication2776400,2025-07-27T15:12:35.717859
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,"A multi-center, adaptive, randomized, platform trial to evaluate the effect of repurposed medicines in outpatients with early coronavirus disease 2019 (COVID-19) and high-risk for complications: the TOGETHER master trial protocol",Gates Open Research,,10.12688/gatesopenres.13304.2,https://experts.mcmaster.ca/display/publication2745874,2025-07-27T15:12:35.717860
Gilmar Reis,reisg1@mcmaster.ca,journal_articles,"A multi-center, adaptive, randomized, platform trial to evaluate the effect of repurposed medicines in outpatients with early coronavirus disease 2019 (COVID-19) and high-risk for complications: the TOGETHER master trial protocol",Gates Open Research,,10.12688/gatesopenres.13304.1,https://experts.mcmaster.ca/display/publication2745876,2025-07-27T15:12:35.717861
Gilmar Reis,reisg1@mcmaster.ca,chapters,"ANÁLISE DOS NÍVEIS DE COLESTEROL TOTAL E FRAÇÕES EM PACIENTES COM EVENTO CORONARIANO AGUDO RECENTE, EM USO ESTÁVEL DE SINVASTATINA 40MG/DIA E ATORVASTATINA 40 MG/ DIA",,,10.22533/at.ed.6662122113,https://experts.mcmaster.ca/display/publication2776413,2025-07-27T15:12:35.717862
Gilmar Reis,reisg1@mcmaster.ca,conferences,Late Clinical Outcomes of Diabetic Patients Randomized in the Occluded Artery Trial (OAT),Circulation,2008,,https://experts.mcmaster.ca/display/publication2443323,2025-07-27T15:12:35.717864
Gilmar Reis,reisg1@mcmaster.ca,conferences,"International patterns in the care of acute myocardial infarction patients in the occluded artery trial (OAT): Characteristics of 1,835 screened patients",Journal of the American College of Cardiology,2003,10.1016/s0735-1097(03)81069-0,https://experts.mcmaster.ca/display/publication2776409,2025-07-27T15:12:35.717865
Gilmar Reis,reisg1@mcmaster.ca,conferences,Role of dobutamine stress echocardiography in predicting high risk of clinical events in patients with rheumatic mitral stenosis,Circulation,2002,,https://experts.mcmaster.ca/display/publication3512738,2025-07-27T15:12:35.717865
Gilmar Reis,reisg1@mcmaster.ca,conferences,Atropine stress echocardiography identifies high risk of clinical events in patients with rheumatic mitral stenosis: Comparison with dobutamine stress echocardiography.,Circulation,1998,,https://experts.mcmaster.ca/display/publication3512739,2025-07-27T15:12:35.717867
Gilmar Reis,reisg1@mcmaster.ca,preprints,Early Treatment with Fluvoxamine Among Patients with COVID-19: A Cost-Consequence Model,,2021,10.1101/2021.12.23.21268352,https://experts.mcmaster.ca/display/publication3236927,2025-07-27T15:12:35.717868
